Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

6 August 2026 A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

Pharma

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

23 July 2026 Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.

More features

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

Brown Rudnick lands largest lateral IP team hire in firm history

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

K&L Gates expands European practice with Munich team hire

Patent litigator joins Baker Botts in London as UPC grows in significance

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

Arnold & Porter adds firepower to ITC practice with new partner hire

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

More on this story

Editor's picks

Editor's picks

More features